It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Molecular determinants governing the evolution of tumor subclones toward phylogenetic branches or fixation remain unknown. Using sequencing data, we model the propagation and selection of clones expressing distinct categories of BRAF mutations to estimate their evolutionary trajectories. We show that strongly activating BRAF mutations demonstrate hard sweep dynamics, whereas mutations with less pronounced activation of the BRAF signaling pathway confer soft sweeps or are subclonal. We use clonal reconstructions to estimate the strength of “driver” selection in individual tumors. Using tumors cells and human-derived murine xenografts, we show that tumor sweep dynamics can significantly affect responses to targeted inhibitors of BRAF/MEK or DNA damaging agents. Our study uncovers patterns of distinct BRAF clonal evolutionary dynamics and nominates therapeutic strategies based on the identity of the BRAF mutation and its clonal composition.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 2111 East 96th St/NE-6, Department of Translational Hematology Oncology Research, Cleveland Clinic, Cleveland, OH, USA; 2111 East 96th St/ND-46, Molecular Medicine Program, Lerner Research Institute, Case Western Reserve University, Cleveland, OH, USA
2 2111 East 96th St/NE-6, Department of Translational Hematology Oncology Research, Cleveland Clinic, Cleveland, OH, USA
3 101, Daehak-Ro, Jongno-Gu, Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea, USA
4 10201 Carnegie Ave/CA-5, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA
5 9500 Euclid Avenue/J4-1, Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, USA
6 9500 Euclid Avenue/M2-141, Department of Pulmonary Medicine, Cleveland Clinic, Cleveland, OH, USA
7 2109 Adelbert Road/BRB, Case Western Reserve University, Department of Genetics, Cleveland, OH, USA
8 2111 East 96th St/NE-6, Department of Translational Hematology Oncology Research, Cleveland Clinic, Cleveland, OH, USA; 10201 Carnegie Ave/CA-5, Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH, USA